Moreover, within the tumor microenvironment and as already proven in other cancers, there are many cells and factors that may inhibit T-cell effector function and hinder the success of effective immunotherapy, such as Treg cells and immunosuppressive cytokines such as IL-10 and TGF-β. Here, TGFB1 is linked to neoplasm.